a Scatter plot showing
the results of the 1770 compound high-throughput phenotypic
screen for enhancers of anti-tumor T-cell function. The majority
of compounds did not elicit any change in tumor spheroid
phenotype and clustered with the DMSO vehicle control samples.
Hit compounds that yielded desirable anti-tumor phenotypes were
broadly classified by their ability to reduce tumor size (Hit
Class I) or size and structure (Hit Class II). Solid lines
indicate the mean for either the spheroid area (y axis) or the spheroid shape
factor (x axis); dotted lines
indicate three standard deviations from the mean. b Example of a hit compound from the
screen. Tumor spheroids treated with the CDK4/6 inhibitor are
shown in three different channels alongside the DMSO negative
control. Scale bars indicate 100 µm.